Journal article
Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group
MG Ison, FG Hayden, AJ Hay, LV Gubareva, EA Govorkova, E Takashita, JL McKimm-Breschkin
Antiviral Research | ELSEVIER | Published : 2021
Abstract
It is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymerase inhibitors and recent approval of baloxavir marboxil, the isirv-AVG held a closed meeting in August 2019 to discuss the impact of resistance to these inhibitors. Follow..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
We gratefully acknowledge helpful discussions with the following: Wendy S. Barclay, Alicia M. Fry, Aeron C. Hurt, John W. McCauley, Nahako Shindo, Norio Sugaya, Reiko Saito, Maria Zambon, Mira C. Patel. EG is supported with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contracts HHSN272201400006C and 75N93021C00016.